Premium
PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Author(s) -
Tam C.S.,
Rule S.,
Le Gouill S.,
Vitolo U.,
Tsao L.C.,
Cavazos N.,
Beaupre D.M.,
Wang M.L.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2440_4
Subject(s) - medicine , venetoclax , tumor lysis syndrome , ibrutinib , mantle cell lymphoma , ven , bendamustine , oncology , gastroenterology , rituximab , lymphoma , chronic lymphocytic leukemia , leukemia , chemotherapy , computer security , computer science
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom